Compare Novo Nordisk A/S (NVO) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Toronto-Dominion Bank — how do they compare? Novo Nordisk A/S trades at $45.81 (market cap $207.85B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Novo Nordisk A/S and Toronto-Dominion Bank are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | TD | |
|---|---|---|
Market Cap | $207.85B | $200.48B |
Sector | Health | Financials |
52-Week High | $63.98 | $124.80 |
52-Week Low | $35.29 | $72.85 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
TD trades at $121.08, down 0.19% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS expected at $1.70. Revenue grew to $61.28 billion in 2025, and net income margin improved to 33.51%. A dividend of $1.12 is scheduled for payment on July 31, 2026.
The outlook is positive given consistent earnings outperformance and a solid dividend, but risks include high debt levels and volatile cash flows. Analyst consensus is bullish with no sell ratings, supporting a favorable medium-term view amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
